On November 10, 2022 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that data from its two lead clinical assets will feature in two poster presentations at the 2022 SITC (Free SITC Whitepaper) (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)) Annual Meeting, being held in Boston November 8-12 (Press release, Alligator Bioscience, NOV 10, 2022, View Source [SID1234623677]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first presentation, entitled "Early pharmacodynamic changes measured by RNA sequencing in peripheral blood from patients in a phase 1 study with mitazalimab, a potent CD40 agonistic IgG1 monoclonal antibody", outlines the evaluation of pharmacodynamic changes by measuring RNA sequencing from peripheral blood samples collected both pre- and post-treatment in a dose escalation study of mitazalimab (CD40 mAb) in patients with advanced stage solid tumors (NCT02829099).
The analysis of the RNA sequencing data clearly demonstrates that mitazalimab induces strong immune responses in patients by activating myeloid cells and B cells. The presented gene expression data confirm the biological activity of mitazalimab, further strengthening its proof of mechanism and potential in solid tumors.
The second presentation, entitled "ATOR-1017, a 4-1BB antibody, demonstrates promising safety and proof of mechanism in a first-in-human study in patients with advanced solid malignancies", outlines new results from Alligator’s Phase 1, first-in-human clinical trial with ATOR-1017, a 4-1BB antibody which is being developed as a tumor-directed therapy for advanced/metastatic cancer (NCT04144842).
Overall, the data showed that ATOR-1017 is safe and well-tolerated at doses up to 900 mg and has shown signs of clinical benefit. No dose-limiting toxicity was observed and the maximum tolerated dose was not reached. Stable disease was achieved as best objective response in 13 (52%) of the 25 patients treated with ATOR-1017, which lasted longer than 6 months for 6 (24%) patients. These data warrant further development of ATOR-1017 in combination with other therapeutic approaches in solid tumors.
"Presenting these two sets of data from our lead clinical assets at such a prominent scientific conference like SITC (Free SITC Whitepaper) is a welcome validation of the work of Alligator’s scientific team and of the potential mitazalimab and ATOR-1017 are both demonstrating in advanced cancers," said Søren Bregenholt, CEO of Alligator Bioscience. "We are very pleased that both data sets support the further advancement of these candidates. We are currently preparing for the next stage of ATOR-1017’s development, while enrolment for the Phase 2 part of the OPTIMIZE-1 study of mitazalimab in pancreatic cancer is making great progress."